SAB Biotherapeutics Analyst Ratings
SAB Biotherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 8.32% | HC Wainwright & Co. | $2 → $1 | Maintains | Buy |
| 10/05/2023 | — | Ladenburg Thalmann | Downgrades | Buy → Neutral | |
| 08/21/2023 | 116.64% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 06/21/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 06/16/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 06/15/2023 | 224.96% | Chardan Capital | → $3 | Reiterates | Buy → Buy |
| 05/17/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 04/27/2023 | 224.96% | Chardan Capital | → $3 | Reiterates | → Buy |
| 04/13/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 04/03/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 11/29/2022 | 333.28% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 08/11/2022 | 224.96% | Chardan Capital | $7 → $3 | Maintains | Buy |
| 05/13/2022 | 658.23% | Chardan Capital | $10 → $7 | Maintains | Buy |
| 04/01/2022 | 983.19% | Chardan Capital | $17 → $10 | Maintains | Buy |
| 11/05/2021 | 1741.42% | Chardan Capital | → $17 | Initiates Coverage On | → Buy |
| 11/02/2021 | 2391.33% | Baird | → $23 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/14/2023 | 8.32% | HC Wainwright & Co. | $2 → $1 | 维护 | 买 |
| 10/05/2023 | — | 拉登堡塔尔曼 | 降级 | 买入 → 中性 | |
| 08/21/2023 | 116.64% | HC Wainwright & Co. | 4 美元 → 2 美元 | 维护 | 买 |
| 06/21/2023 | 333.28% | HC Wainwright & Co. | → 4 美元 | 重申 | 购买 → 购买 |
| 06/16/2023 | 333.28% | HC Wainwright & Co. | → 4 美元 | 重申 | 购买 → 购买 |
| 06/15/2023 | 224.96% | 查丹资本 | → 3 美元 | 重申 | 购买 → 购买 |
| 05/17/2023 | 333.28% | HC Wainwright & Co. | → 4 美元 | 重申 | 购买 → 购买 |
| 04/27/2023 | 224.96% | 查丹资本 | → 3 美元 | 重申 | → 购买 |
| 04/13/2023 | 333.28% | HC Wainwright & Co. | → 4 美元 | 重申 | → 购买 |
| 04/03/2023 | 333.28% | HC Wainwright & Co. | → 4 美元 | 重申 | → 购买 |
| 2022 年 11 月 29 日 | 333.28% | HC Wainwright & Co. | → 4 美元 | 启动覆盖范围开启 | → 购买 |
| 08/11/2022 | 224.96% | 查丹资本 | 7 美元 → 3 美元 | 维护 | 买 |
| 05/13/2022 | 658.23% | 查丹资本 | 10 美元 → 7 美元 | 维护 | 买 |
| 04/01/2022 | 983.19% | 查丹资本 | 17 美元 → 10 美元 | 维护 | 买 |
| 2021 年 5 月 11 日 | 1741.42% | 查丹资本 | → 17 美元 | 启动覆盖范围开启 | → 购买 |
| 11/02/2021 | 2391.33% | 贝尔德 | → 23 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for SAB Biotherapeutics (SABS)?
SAB Biotherapeutics（SABS）的目标价格是多少？
The latest price target for SAB Biotherapeutics (NASDAQ: SABS) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $1.00 expecting SABS to rise to within 12 months (a possible 8.32% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月14日公布了SAB Biotherapeutics（纳斯达克股票代码：SABS）的最新目标股价。该分析公司将目标股价定为1.00美元，预计SABS将在12个月内升至12个月内（可能上涨8.32％）。去年有11家分析公司公布了评级。
What is the most recent analyst rating for SAB Biotherapeutics (SABS)?
SAB Biotherapeutics（SABS）的最新分析师评级是多少？
The latest analyst rating for SAB Biotherapeutics (NASDAQ: SABS) was provided by HC Wainwright & Co., and SAB Biotherapeutics maintained their buy rating.
HC Wainwright & Co. 提供了SAB Biotherapeutics（纳斯达克股票代码：SABS）的最新分析师评级，SAB Biotherapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for SAB Biotherapeutics (SABS)?
SAB Biotherapeutics（SABS）的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SAB Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SAB Biotherapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与SAB Biotherapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。SAB Biotherapeutics的最新评级是在2023年11月14日发布的，因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating SAB Biotherapeutics (SABS) correct?
分析师对SAB Biotherapeutics（SABS）的评级是否正确？
While ratings are subjective and will change, the latest SAB Biotherapeutics (SABS) rating was a maintained with a price target of $2.00 to $1.00. The current price SAB Biotherapeutics (SABS) is trading at is $0.92, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的SAB Biotherapeutics（SABS）评级维持不变，目标股价为2.00美元至1.00美元。SAB Biotherapeutics（SABS）目前的交易价格为0.92美元，超出了分析师的预期区间。